DE69022290T2 - Lebende Impfstoffe. - Google Patents

Lebende Impfstoffe.

Info

Publication number
DE69022290T2
DE69022290T2 DE69022290T DE69022290T DE69022290T2 DE 69022290 T2 DE69022290 T2 DE 69022290T2 DE 69022290 T DE69022290 T DE 69022290T DE 69022290 T DE69022290 T DE 69022290T DE 69022290 T2 DE69022290 T2 DE 69022290T2
Authority
DE
Germany
Prior art keywords
live vaccines
attenuating
bacteria
vaccines
concerned
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69022290T
Other languages
English (en)
Other versions
DE69022290D1 (de
Inventor
Gordan Dougan
Steven Neville Chatfield
Christopher Francis Higgins
Charles James Dorman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LISTER PREVENTIVE MED
University of Dundee
Royal Society
Wellcome Foundation Ltd
Original Assignee
LISTER PREVENTIVE MED
University of Dundee
Royal Society
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LISTER PREVENTIVE MED, University of Dundee, Royal Society, Wellcome Foundation Ltd filed Critical LISTER PREVENTIVE MED
Application granted granted Critical
Publication of DE69022290D1 publication Critical patent/DE69022290D1/de
Publication of DE69022290T2 publication Critical patent/DE69022290T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/826—Bacterial vaccine for avian species, e.g. poultry or other birds
DE69022290T 1989-05-30 1990-05-29 Lebende Impfstoffe. Expired - Lifetime DE69022290T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898912330A GB8912330D0 (en) 1989-05-30 1989-05-30 Live vaccines

Publications (2)

Publication Number Publication Date
DE69022290D1 DE69022290D1 (de) 1995-10-19
DE69022290T2 true DE69022290T2 (de) 1996-09-05

Family

ID=10657547

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69022290T Expired - Lifetime DE69022290T2 (de) 1989-05-30 1990-05-29 Lebende Impfstoffe.

Country Status (9)

Country Link
US (2) US5851519A (de)
EP (1) EP0400958B1 (de)
JP (1) JP3024982B2 (de)
AT (1) ATE127694T1 (de)
DE (1) DE69022290T2 (de)
DK (1) DK0400958T3 (de)
ES (1) ES2077028T3 (de)
GB (1) GB8912330D0 (de)
GR (1) GR3017535T3 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811105A (en) * 1987-12-23 1998-09-22 Glaxo Wellcome, Inc. Vaccines containing bacteria attenuated by mutations in two genes of the aromatic amino acid biosynthetic pathway
GB9007194D0 (en) * 1990-03-30 1990-05-30 Wellcome Found Live vaccines
CZ285118B6 (cs) * 1991-03-05 1999-05-12 The Wellcome Foundation Limited Exprese rekombinačních proteinů v oslabených bakteriích
US6680182B1 (en) * 1992-07-31 2004-01-20 Acambis Research Limited Expression of recombinant fusion proteins in attenuated bacteria
US6153406A (en) * 1993-07-23 2000-11-28 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B
AU7408494A (en) * 1993-07-30 1995-02-28 University Of North Carolina At Chapel Hill, The Production of gonorrheal pi proteins and vaccines in e. coli and salmonella
US6254874B1 (en) * 1995-04-13 2001-07-03 President And Fellows Of Harvard College Attenuated auxotrophic microorganisms having a combination of non-attenuating mutations and method for making same
AUPN631395A0 (en) * 1995-11-02 1995-11-23 Commonwealth Scientific And Industrial Research Organisation Vaccine and biological vector(II)
US6770275B1 (en) 1996-05-31 2004-08-03 Akzo Nobel N.V. Live attenuated RTC-producing bacteria of the family
EP0810283A3 (de) * 1996-05-31 1997-12-10 Akzo Nobel N.V. Lebende attenuierte RTX-produzierende Bakterien aus der Familie pasteurellaceae
US7011836B1 (en) * 1997-08-21 2006-03-14 De Staat Der Nederlanden, Vertenwoordigd Door De Minister Van Welzijn, Volksgezondheil En Cultuur Mutants of gram negative mucosal bacteria and application thereof in vaccines
NZ503376A (en) 1997-09-10 2002-10-25 Vion Pharmaceuticals Inc Genetically modified Salmonella sp having a modified msbB gene useful for treating tumours
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US6905691B1 (en) 1997-12-11 2005-06-14 Celltech Pharma Europe Limited Vaccines containing attenuated bacteria
GB9726233D0 (en) * 1997-12-11 1998-02-11 Medeva Europ Ltd Vaccines containing attenuated bacteria
GB9806449D0 (en) 1998-03-25 1998-05-27 Peptide Therapeutics Ltd Attenuated bacteria useful in vaccines
US6413768B1 (en) 1998-12-02 2002-07-02 University Of Maryland Expression plasmids
US8076130B2 (en) * 1998-12-02 2011-12-13 University Of Maryland, Baltimore Plasmid maintenance system for antigen delivery
AU776562B2 (en) * 1998-12-02 2004-09-16 University Of Maryland At Baltimore Plasmid maintenance system for antigen delivery
CA2366462C (en) * 1998-12-04 2011-08-09 University Of Manitoba Two-step immunization procedure against chlamydia infection
US6962696B1 (en) 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
NZ519477A (en) * 1999-12-23 2004-04-30 Microscience Ltd Attenuated microorganisms for the treatment of infection
US6872547B1 (en) 2000-10-11 2005-03-29 Washington University Functional balanced-lethal host-vector systems
JP4886122B2 (ja) * 2001-05-31 2012-02-29 日水製薬株式会社 腸炎ビブリオ検出用培地
WO2002102409A1 (en) * 2001-06-19 2002-12-27 Medical Research Council Inactivated mycobacterial ompatb and uses thereof
GB0121998D0 (en) 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
AUPR977601A0 (en) * 2001-12-28 2002-01-31 Delta Biotechnology Limited Defective entities and uses therefor
EP1499191B1 (de) * 2002-04-15 2012-05-09 Washington University in St. Louis Regulierte attenuierung von lebendimpfstoffen zur verbesserung der kreuzimmunitätsschutzfunktion
US7297338B2 (en) 2003-05-14 2007-11-20 Wyeth Avian vaccine composition for the protection of poultry against disease and infection caused by E. coli and Salmonella
US7357935B2 (en) * 2003-05-14 2008-04-15 Wyeth Avian E. coli vaccine for protection against colibacillosis
US7364745B2 (en) * 2004-02-06 2008-04-29 Virginia Tech Intellectual Properties, Inc. Development of a live, attenuated, recombinant vaccine for Brucellosis
GB2412259A (en) * 2004-03-16 2005-09-21 Wolfson Ltd A CMOS folded-cascode operational amplifier having low flicker noise
CN1276076C (zh) * 2004-12-14 2006-09-20 华东理工大学 一种鳗弧菌野生毒株的无标记基因缺失减毒突变株及其应用
FR2898276B1 (fr) * 2006-03-08 2008-07-25 Univ Claude Bernard Lyon Nouveaux vaccins destines au traitement ou a la prevention des infections par parasites de la famille des taenidae et en particulier du genre echinococcus
BR112016023915B1 (pt) 2014-04-15 2024-03-12 Griffith University Usos de fragmento de proteína m e composição
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
WO2021102505A1 (en) 2019-11-25 2021-06-03 Griffith University Immunogenic protein against gonococcal infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB184086A (en) * 1921-09-16 1922-08-10 William Henry Taylor Improvements relating to endless conveyors
IL59663A (en) * 1980-03-19 1983-02-23 Univ Ramot Vaccines obtained from bacterial mutant strains of enterobacteriaceae and pseudomonaceae
US4735801A (en) * 1982-09-07 1988-04-05 Board Of Trustees Of Leland Stanford Jr. University Novel non-reverting salmonella live vaccines
US4837151A (en) * 1980-05-19 1989-06-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford University Live vaccines comprising two mutations and foreign antigen
DK189788D0 (da) * 1988-04-07 1988-04-07 Wolf Watz Hans Vaccine
AU645489B2 (en) * 1989-03-31 1994-01-20 Washington University Vaccines containing avirulent phoP-type microorganisms

Also Published As

Publication number Publication date
DK0400958T3 (da) 1996-01-15
EP0400958A3 (de) 1991-09-18
US5527529A (en) 1996-06-18
GB8912330D0 (en) 1989-07-12
EP0400958A2 (de) 1990-12-05
US5851519A (en) 1998-12-22
JPH03117481A (ja) 1991-05-20
ES2077028T3 (es) 1995-11-16
ATE127694T1 (de) 1995-09-15
GR3017535T3 (en) 1995-12-31
JP3024982B2 (ja) 2000-03-27
EP0400958B1 (de) 1995-09-13
DE69022290D1 (de) 1995-10-19

Similar Documents

Publication Publication Date Title
DE69022290T2 (de) Lebende Impfstoffe.
MX9203458A (es) Segmentos inmunogenicos que contienen glicoproteinas quimericas de las glicoproteinas de virus sincitial respiratorio humano.
MA20411A1 (fr) Procede de preparation de polypeptides ayant l'activite du gamma-interferon humain
ATE184193T1 (de) Verwendung von n-acylaminoalkoholen zur herstellung eines arzneimittels zur behandlung von mastzellerkrankungen
DE3776367D1 (de) Sterilisationsverfahren.
DE3681144D1 (de) Verwendung biologisch aktiver copolymere zur herstellung eines arzneimittels zur stimulierung des wachstums von tieren.
KR950700079A (ko) 이식체-대-숙주 질환을 억제하기 위한 인터루킨-10의 용도(Use of interleukin-10 to suppress graft-vs. -host disease)
ATE99669T1 (de) N-2,3-butadienyl-tri-aminoalkanderivate.
DE3850154T2 (de) Verwendung von Gepiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung atypischer Depression.
DE69333812D1 (de) Endo-Xyloglucan-Transferase
DE69432856D1 (de) Zufuhr von genprodukten mittels mesangium-zellen
DK0406745T3 (da) Antibiotiske GE 2270 faktorer A1, A2, A3 og H
YU47473B (sh) Postupak za dobijanje vakcine protiv trovanja krvi živine escherichijom coli
DE68904131D1 (de) Schweinenierenzellkultur und ihre verwendung fuer die herstellung von vakzinen.
JPS6480298A (en) Production of human proapolipoprotein a-i-like protein
ATE48531T1 (de) Verfahren zum sterilisieren von rekombinantem mikroorganismus.
DE69032471D1 (de) Proteine mit onkostatin-m-aktivität und verfahren zu ihrer herstellung
SE8002898L (sv) Biologiskt aktiv substans och forfarande for framstellning derav
IT1276765B1 (it) Gene del cromosoma x umano e proteina codificata da detto gene.

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8364 No opposition during term of opposition